March 8, 2022, Vol 327, No. 10, Pages 897-1003
Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021
Caroline L. Behr, AB; Karen E. Joynt Maddox, MD, MPH; Ellen Meara, PhD; et al.
free access has active quiz
JAMA. 2022;327(10):980-983. doi:10.1001/jama.2022.1243
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.